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Available online xxxxBackground: Clostridium difﬁcile ribotype-027, ribotype-078, and ribotype-017 are virulent and epidemic line-
ages. Trehalosemetabolism variants in these ribotypes, combinedwith increased human trehalose consumption,
have been hypothesised to have contributed to their emergence and virulence.
Methods: 5232 previouslywhole-genome sequenced C. difﬁcile isolateswere analysed. Clinical isolateswere used
to investigate the impact of trehalose metabolism variants on mortality. Import data were used to estimate
changes in dietary trehalose. Ribotype-027 virulence was investigated in a clinically reﬂective gut model.
Findings: Trehalose metabolism variants found in ribotype-027 and ribotype-017 were widely distributed
throughout C. difﬁcile clade-2 and clade-4 in 24/29 (83%) and 10/11 (91%) of sequence types (STs), respectively.
The four-gene trehalose metabolism cluster described in ribotype-078 was common in genomes from all ﬁve
clinically-important C. difﬁcile clades (40/167 [24%] STs).
The four-gene cluster was variably present in 208 ribotype-015 infections (98 [47%]); 27/208 (13%) of these pa-
tients diedwithin 30-days of diagnosis. Adjusting for age, sex, and infecting ST, therewas no association between
30-day all-cause mortality and the four-gene cluster (OR 0.36 [95%CI 0.09–1.34, p= 0.13]).
Synthetic trehalose imports in the USA, UK, Germany and the EUwere b 1 g/capita/year during 2000–2006, and
b 9 g/capita/year 2007–2012, compared with dietary trehalose from natural sources of ~100 g/capita/year.
Trehalose supplementation did not increase ribotype-027 virulence in a clinically-validated gut model.
Interpretation: Trehalosemetabolismvariants are common inC. difﬁcile. Increases in total dietary trehalose during
the early-mid 2000s C. difﬁcile epidemic were likely relatively minimal. Alternative explanations are required to
explain why ribotype-027, ribotype-078 and ribotype-017 have been successful.
Funding: National Institute for Health Research. Gut model experiments only: Hayashibara Co. Ltd.
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Epidemiology1. Introduction
Clostridium difﬁcile is an important cause of healthcare-associated di-
arrhoea. The emergence and global spread of the hypervirulent
ribotype-027 strain has made control and prevention of C. difﬁcile infec-
tion, CDI, a major priority for healthcare systems.y of Oxford, UK.
. This is an open access article under
ot, A.M. Buckley, et al., Clostrid
variably present..., EBioMedicThe reasons for the success of ribotype-027 are likely multifactorial,
including very probably ﬂuoroquinolone resistance [1], and possibly
other adaptions to the hospital environment [2]. Acquisition of ﬂuoro-
quinolone resistance, on two separate occasions, occurred around the
start of the epidemic spread of ribotype-027 throughout the USA,
Canada and Europe [1]. High levels of ﬂuoroquinolone resistance are
also seen in other healthcare-associated ribotypes, including 001, 018/
356 and 176 [3]. Levels of ribotype-027, and other ﬂuoroquinolone-
resistant CDI fell markedly following reductions in ﬂuoroquinolone
usage in the UK [4].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
ium difﬁcile trehalose metabolism variants are common and not asso-
ine, https://doi.org/10.1016/j.ebiom.2019.04.038
Research in context
Evidence before this study
Clostridium difficile ribotype-027 and ribotype-078 are two viru-
lent and epidemic lineages, and ribotype-017 is widely present in
Asia. Acquisition of fluoroquinolone resistance by ribotype-027
likely promoted its spread. However, the reasons for the success
of these ribotypes are likely multifactorial. Trehalose metabolism
variants in ribotypes 027, 078 and 017, combined with recent in-
creases in human dietary intake of the sugar trehalose, have been
hypothesised to have helped select for their emergence and con-
tributed to their virulence. We searched Pubmed and Google
Scholar using the search term “Clostridiumdifficile” and “trehalose”
on 22 January 2019. We also identified references citing search
results using Google Scholar. Trehalose metabolism variants in
C. difficile confer the ability to metabolise low concentrations of
trehalose and that this provides a competitive advantage in
growthmedia and laboratory animals. Enhanced trehalose metab-
olism in ribotype-027 has been associated with increased viru-
lence in a mouse model of C. difficile infection. However, the
distribution of trehalosemetabolism variants within the overall ge-
netic diversity ofC. difficile, their role in patient outcomes and the
extent of increases in dietary trehalose from synthetic production
are incompletely described to date.
Added value of this study
The trehalose metabolism variant found in ribotype-027 (TreR
L172I) is widely distributed throughout C. difficile clade-2, and
the variant in ribotype-017 (TreR C171S) is found in all but one se-
quence type (ST) in clade-4. The four-gene trehalose metabolism
cluster described in ribotype-078 is common in genomes of STs
representing all five clinically important C. difficile clades and not
restricted to clade-5 as previously proposed.Within closely related
genomes from ribotype-015, with and without the four-gene tre-
halose metabolism cluster, there was no evidence of an associa-
tion between 30-day all-cause mortality and the four-gene
cluster. Annual imports per capita of synthetic trehalose into the
USA, UK, Germany and the EU as a whole during 2000 to 2006,
i.e. around the start of the ribotype-027 outbreak, accounted for
only a minimal proportion of total dietary trehalose intake. Treha-
lose supplementation, at levels found in the human gut, did not in-
crease ribotype-027 virulence in a triple phase chemostat gut
model, and resulted in supressed toxin production.
Implications of all the available evidence
Trehalose metabolism variants are common within the overall ge-
netic diversity of clinical C. difficile and associated with ancient
C. difficile population structures. Therefore, the role of trehalose
metabolism variants in the rise of ribotypes 027 and 078 specifi-
cally to clinical importance is questionable. These variants are
not unique to these ribotypes and increases in total dietary treha-
lose between 2000 and 2012were relatively minimal as a propor-
tion of total dietary trehalose intake. In contrast to data from a
mouse model of ribotype-027 infection, the trehalose four-gene
cluster is not associated with increased mortality in human infec-
tions with another commonly circulating C. difficile genotype,
ribotype-015. Alternative explanations are required to explain
why ribotype-027 and ribotype-078 have been successful.
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prevalent lineages and is also variably present in the successful
ribotype-078 [3], which has been associated with livestock farming
rather than healthcare [5]. Therefore, additional potential explanations
for the success of ribotypes 027 and 078 have been explored. A recent
study by Collins et al. [6] proposed that trehalose metabolism variants
in ribotypes 027 and 078, combined with recent increases in human di-
etary trehalose, have played a signiﬁcant role in the emergence of these
epidemic strains. Two independentmechanismswere identiﬁed that fa-
cilitate metabolism of low concentrations of the disaccharide sugar tre-
halose. In ribotype-027 and closely-related ribotypes from C. difﬁcile
clade-2, a point mutation in the treR gene confers a L172I substitution
in a transcriptional regulator, TreR, leading to higher expression of the
phosphotrehalase enzyme TreA. Ribotype-078 and closely-related
clade-5 strains have a four-gene cluster including a phosphotrehalase
and a potential trehalose transporter, which Collins et al report is absent
from other clades [6]. The same authors have since identiﬁed a second
treR variant with a C171S amino acid substitution in TreR in ribotype-
017 (from clade-4) [7]; notably these strains are also ﬂuoroquinolone
resistant [8]. Enhanced trehalose metabolism in ribotype-027was asso-
ciated with increased virulence in a mouse model of CDI [6].
We investigated the plausibility that trehalose metabolism variants
conferred a selective advantage for ribotypes 027 and 078 by evaluating
how common these variants are within the total genetic diversity of
clinical C. difﬁcile using previously sequenced isolates. Within a com-
monly circulating genotype, ribotype-015, we identiﬁed variable pres-
ence of the trehalose four-gene cluster, which allowed assessment of
the impact of variant acquisition on virulence in patients. We also eval-
uated the extent towhich imports of synthetic trehalose altered total di-
etary trehalose intake during the rise of ribotypes 027 and 078 in
Europe, the USA and Canada.2. Materials and methods
2.1. Genomic data and sequence analysis
Data from 5386 previously whole-genome sequenced C. difﬁcile iso-
lates, predominantly cultured from humans with CDI were obtained.
These data include clinical isolates from hospital and community pa-
tients with CDI from Oxfordshire, UK (2006–2013) [4,9,10], Leeds, UK
(2005–2013) [9,10], and the two licensing trials of ﬁdaxomicin in
Europe, USA, and Canada (2006–2009) [11,12]. Additionally, genomes
from a pan-European survey of CDI [3], healthy children in the UK
[13], and ribotype and toxinotype reference collections were included.
Raw sequence reads were de novo assembled; 5,232 genomes passed
quality control ﬁlters. Assemblies were used to determine multi-locus
sequence types (STs) and associated clades. BLAST searches were used
to identify treR variants and the presence of the four-gene cluster de-
scribed by Collins et al [6], see supplement for details and a full list of se-
quences with European Nucleotide Archive identiﬁers (Table S1).
For phylogenetic analysis, to avoid over-representing some lineages
as a result of clonal transmission, an example of each sequence type (ST)
was chosen at random.Where genomes of the same ST contained differ-
ent trehalose metabolism variants, one random genomewith andwith-
out the variant was included. For these genomes, sequence data were
mapped against the 630 reference genome as previously described
[14]. Sequences were compared using single nucleotide polymor-
phisms, SNPs, obtaining differences between sequences frommaximum
likelihood phylogenies constructed from mapped read data using
PhyML version 3.1 [15] (with generalized time-reversible substitution
model and “BEST” tree topology search algorithm), and corrected for re-
combination using ClonalFrameML version 1.25 [16] (with default set-
tings). Phylogenetic clustering of presence of the four-gene clusterium difﬁcile trehalose metabolism variants are common and not asso-
ine, https://doi.org/10.1016/j.ebiom.2019.04.038
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netic distances from the phylogeny and pairwise comparisons of the
concordance of the presence or absence of the four-gene cluster. The
test was performed using R 3.5.3 with 10,000 permutations. For STs
with any genome containing the trehalose four-gene cluster, two fur-
ther phylogenies were similarly determined using i) the mapped data
and ii) the sequence of the trehalose four-gene cluster. Intact DNA se-
quences spanning the four-gene clusterwere extracted from the assem-
bled contigs, aligned using MUSCLE [17], and used as input for this
maximum likelihood phylogeny.2.2. Patient outcome data
Thirty-day all-causemortality was obtained for all patients fromOx-
ford, Leeds and theﬁdaxomicin trials usinghospital and trial records, re-
spectively, and for non-trial patients veriﬁed against the UK National
Health Service Spine providing information on mandatory death
registrations.
Multivariable logistic regressionwas used to determine the relation-
ship between 30-day all-causemortality and the presence or absence of
the trehalose four-gene cluster. Short-term all-cause mortality was
analysed rather than disease-speciﬁc mortality because attribution of
mortality to a single cause in this setting is problematic, as patients fre-
quently have multiple co-morbidities and prior infection(s) with path-
ogens other than C. difﬁcile. Additional factors available in the datasets
were adjusted for, including age, sex and the infecting ST, accounting
for non-linearity in continuous factors usingmultiple fractional polyno-
mials. Interactions between factors were included in the ﬁnal model if
the interaction p-value was b0.05. Stata 14.1 (Stata Corp, College Sta-
tion, TX) was used.2.3. National CDI surveillance data and trehalose import data
CDI incidence data was obtained for England, USA, and Germany.
Data from Englandwere obtained from themandatory national surveil-
lance undertaken by Public Health England. Mandatory reporting of all
hospital and community CDI cases in patients ≥65 years was introduced
in 2004 and changed to include patients ≥2 years during 2007. Reported
incidence for 2004–2007 was therefore scaled up, to be representative
of patients ≥2 years, using the ratio of cases in patients ≥2 years and
≥ 65 years in 2008. Voluntary reporting data were used to estimate
the total number of cases prior to 2004, scaling the reported number
of cases by the ratio of voluntary to scaled mandatory reports in 2004
[4]. Previously published data were used on the number of CDI cases
per 1000 hospital discharges in the USA between 2001 and 2010 [18]
and from the German national CDAD-KISS surveillance scheme [19].
Overall CDI incidence provides a marker of ribotype-027 and ribotype-
078 incidence, in particular as ribotype-027 has been largely responsi-
ble for recent rises and falls in overall CDI incidence, e.g. in the UK [4]
and USA [20]. CDI incidence was compared with trehalose imports per
country (as a proxy for sales and consumption) supplied by the princi-
pal global supplier of trehalose, Hayashibara Co. Ltd.Table 1
Prevalence of trehalose metabolism variants in 5232 previously sequenced Clostridium difﬁcile
Clade treR
Wildtype L172I substitution C171S
1 3310
2 6 1289 2
3
4 1a 96a
5 374
Novel/not determined 5
a A single clade-4 genome contained nucleotides consistent with a mix of wildtype and the
Please cite this article as: D.W. Eyre, X. Didelot, A.M. Buckley, et al., Clostrid
ciated with adverse patient outcomes when variably present..., EBioMedic2.4. In vitro gut model
We determined the effect of trehalose, glucose or saline supplemen-
tation on CDI, using a well validated and clinically reﬂective gut model,
previously described in detail [21,22]. Triple stage chemostat models
were seededwith 30g of the samepooled faecal slurry fromﬁvehealthy
human donors and allowed to equilibrate before adding C. difﬁcile
ribotype-027 strain 210 (CD027) [23] spores at days 14 and 24. From
previous whole-genome sequencing [24], this strain, in common with
other ribotype-027 isolates, contains the L172I substitution in TreR.
Sugar/saline supplementation was undertaken for 28 days from
day 14 in three separate parallel models, each run once: trehalose
(560 mM), glucose (1120 mM) or saline three times daily. The dosing
regimens were sufﬁcient to achieve ﬁnal trehalose and glucose concen-
trations in the model of 10 mM and 20 mM, respectively, i.e. consistent
with levels observed in humans consuming trehalose [25,26].
Clindamycin was instilled from day 24 for 8 days to create themicrobial
niche to allow CDI. Total C. difﬁcile and C. difﬁcile spore counts, and toxin
levels were obtained on day 3, 10 and daily from day 14 in triplicate
until day 55. Presence of any C. difﬁcile toxin was detected using a
vero cell cytotoxicity assay [22].
2.5. Role of the funding source
The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
3. Results
3.1. Sequence data and sequence analysis
Data from 5232 previously whole-genome sequenced C. difﬁcile iso-
lates were assembled and analysed (Table 1). The treR mutant confer-
ring a L172I substitution was restricted to clade-2 as previously
described [6]. However it was widely present within clade-2, in 24/29
(83%) STs (both clinically important and rarely isolated), and therefore
does not confer a selective advantage unique to ribotype-027 or speciﬁc
to other successful lineages from clade-2 such as ribotype-176 and
ribotype-244 [27]. Similarly the second treR variant conferring a C171S
amino acid substitution, described in ribotype-017 [7], was a clade
rather than ribotype-speciﬁc variant, with only one of 11 STs in clade-
4 lacking the substitution. The C171S substitution was also found in a
subset of ST41 isolates from clade-2 (while ST41 includes the
ribotype-244 lineage that has recently spread across Australia, these
outbreak isolates [28] contained the L172I variant rather than C171S).
Thus, variants in treR appear to be clade-speciﬁc, i.e. ancient polymor-
phisms, that are present in nearly all STs in two of the ﬁve C. difﬁcile
clades.
In contrast to Collins et al [6], the four-gene cluster was found to be
variably present in genomes representing all ﬁve C. difﬁcile clades, and
not restricted to clade-5 as proposed previously (Fig. 1). Instead of con-
ferring a selective advantage limited to ribotype-078/ST11 and related
genomes, 40/167 (24%) STs represented contained the four-gene clus-
ter, including 33 STs from outside clade-5. Despite the presence of thegenomes.
Four-gene insertion
substitution treR gene not detected Absent Present
2 2985 327
1 1285 13
145 145
94 4
4 370
5
C171S substitution; this genome is not included in the treR columns of the table.
ium difﬁcile trehalose metabolism variants are common and not asso-
ine, https://doi.org/10.1016/j.ebiom.2019.04.038
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Fig. 1. Phylogenetic distribution of trehalose metabolism variants. ST, muti-locus sequence type. One representative of each ST is shown. The most common ribotype / ST equivalents for
ribotypes 027, 078 and 017 are shown. Where different isolates of the same ST contained sequences with differing trehalose variants, (e.g. different examples of the ST were positive or
negative for the four-gene cluster) one example of each is shown, denoted, e.g. ST44a, ST44b. The tree depicts a maximum likelihood phylogeny corrected for recombination and with
branch lengths measured in units of single nucleotide polymorphisms, SNPs.
4 D.W. Eyre et al. / EBioMedicine xxx (2019) xxxfour-gene cluster, many of these STs are not commonly isolated from
human CDI cases (see Table S2 in supplement). Where present, the
four-gene cluster was conserved in a form likely to be functional, with
a different treX starting position to that previously reported (see supple-
ment, Fig. S1).
Additionally, genomes from clade-3 consistently lacked the canoni-
cal treR gene, but all contained the four-gene cluster, suggesting strong
historical evolutionary pressure to retain trehalose metabolism
(Table 1). Three STswithin clade-2 and three within clade-4 were iden-
tiﬁed, which contained both a treR variant (L172I or C171S, respec-
tively) and the four-gene insertion (Fig. 1). It may be noteworthy that
even with the genetic potential to encode both mechanisms of en-
hanced trehalose metabolism, these genotypes are clinically rare,Please cite this article as: D.W. Eyre, X. Didelot, A.M. Buckley, et al., Clostrid
ciated with adverse patient outcomes when variably present..., EBioMedicalthough whether the two variants act in an additive manner remains
to be demonstrated.
It is likely therefore that trehalose metabolism variants have been
established in C. difﬁcile long before recent rises in dietary trehalose in-
take since 2000. Collins et al. [6] report that ribotype-027 isolates from
1985 and 1988 both contain the treR L172I mutation. A phylogeny
based on concatenated sequence data from the four-gene cluster fol-
lows a very similar structure to the phylogeny based on the whole ge-
nome (Fig. 2), providing further evidence that the four-gene insertion
predates recent rises in ribotype-078. Additionally, there is clustering
of the four-gene insertion within Clade 1 (Fig. 1, Mantel test p b
0.001), with the clusters sharing common ancestors that are several
thousand SNPs distinct from the tips of each cluster. The mostium difﬁcile trehalose metabolism variants are common and not asso-
ine, https://doi.org/10.1016/j.ebiom.2019.04.038
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Fig. 2.Phylogenybased on the four-gene trehalosemetabolismcluster sequences. Intact DNA sequences spanning the four-gene clusterwere extracted from the assembled contigs, aligned
and used as input for this maximum likelihood phylogeny. Sequence tips are labelled by their ST, and coloured by clade demonstrating that the phylogeny derived from the four-gene
cluster sequence alone follows the population structure of the whole genome sequences.
Table 2
Relationship between trehalose four-gene cluster presence and 30-day mortality from
ribotype-015 (ST10/ST44) C. difﬁcile infection. There was no evidence for a non-linear re-
lationship between mortality and age using multiple fractional polynomials (p = 0.80).
There were no signiﬁcant interactions (all p N 0.05).
Factor Alive,
n (%) /
median
(IQR)
Died,
n (%) /
median
(IQR)
Univariable
OR (95% CI)
p
value
Multivariable
OR (95% CI)
p
value
n 181 27
Age, years OR
per 10-year
increase
73
(59–82)
84
(69–88)
1.42
(1.06–1.90)
0.02 1.45
(1.08–1.34)
0.01
Sex
Female 110
(88%)
15
(12%)
Male 71
(86%)
12
(14%)
1.23
(0.55–2.80)
0.61 1.27
(0.55–2.95)
0.58
ST
ST44 103
(88%)
14
(12%)
ST10 78
(86%)
13
(14%)
1.23
(0.55–2.76)
0.62 0.55
(0.15–2.00)
0.36
Four-gene cluster
Absent 93
(85%)
17
(15%)
Present 88
(90%)
10
(10%)
0.62
(0.27–1.43)
0.26 0.36
(0.09–1.34)
0.13
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quired a limited number of times, and lost more recently by STs within
these clusterswithout the insertion. These results, togetherwith rates of
C. difﬁcile evolution (~1 SNP / genome / year) [14], suggest that the four-
gene insertion, along with the L172I variant in clade-2 and C171S in
clade-4, are likely to have been stably present in C. difﬁcile for thousands
of years with variable presence being caused by loss rather than gain
over time.3.2. Patient outcome data
The variable presence and absence of the four-gene cluster in other-
wise highly related strains from patients with disease provides an op-
portunity to test the hypothesis that trehalose metabolism variation
results in virulence that is responsible for the adverse outcomes seen
in patients with ribotypes 027 and 078. Ribotype-015, a commonly cir-
culating lineage [29], equivalent to ST10 and ST44, variably contains the
four-gene cluster. From previous hospital and community patients with
ribotype-015 CDI we obtained 208 whole-genome sequences with
matched outcome data, 98 (47%) with the four-gene cluster. A total of
27 (13%) died within 30 days of diagnosis. Adjusting for patient age,
sex, and infecting ST, there was no evidence of any association between
30-day all-cause mortality and the presence of the four-gene cluster,
multivariable odds ratio 0.36 (95% conﬁdence interval 0.09–1.34, p =
0.13, Table 2).ium difﬁcile trehalose metabolism variants are common and not asso-
ine, https://doi.org/10.1016/j.ebiom.2019.04.038
Fig. 3. Temporal relationship between C. difﬁcile incidence and trehalose imports. Panel A shows imports of trehalose per capita by year. Trehalose import data were provided by
Hayashibara Co. Ltd. Population denominators were obtained from the UK Ofﬁce of National Statistics, the United States Census Bureau and the European Commission's Eurostat. Panel
B shows estimated total CDI cases per 100 k population in England by year and rates of inpatient CDI per 1000 discharges in the USA and Germany.
Fig. 4. Gut model timeline, total C. difﬁcile counts and toxin detection. CD, C. difﬁcile; CFU, colony forming units. Toxin production is a semi-quantitative assay; the scale provided is in log
arbitrary units.
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To assess the plausibility of synthetic trehalose having substantially
altered diets in the USA and Europe from 2000 onwards, i.e. at the
same time as CDI incidence increased, we obtained the imported vol-
umes of trehalose and combined these with available population statis-
tics. Fig. 3A shows imports of trehalose per capita per year between
2000 and 2012 in the USA, UK, Germany and the rest of the European
Union (EU). Annual imports of trehalose in the USA, UK, Germany and
the EU as a whole were b 1 g per capita per year from 2000 to 2006,
and increased subsequently until 2012, variably across countries, but
remained b9 g per capita per year. Fig. 3B shows the estimated annual
total incidence of CDI in England (representing 84% of the UK popula-
tion) and incidence per 1000 admissions/discharges in hospital inpa-
tients in Germany and the USA. Data from England and the USA [18]
show a rise in incidence peaking in mid 2000s, followed by a fall in
the UK and stable levels in the USA. In Germany, a smaller rise in inci-
dence is seen in the later 2000s. Comparison of the temporal trends in
Fig. 3A and B shows that the increase in trehalose imports postdates
the start of the CDI epidemic by at least 5 years.
3.4. In vitro gut model
Total C. difﬁcile and spore recovery rateswere similar in the three gut
models, instilled with trehalose, glucose or saline (Fig. 4, Fig. S2). Spikes
in C. difﬁcile recoverywere seen after addition of spores at day 14 and 24
but were only sustained after induction of simulated CDI with
clindamycin. Toxin production was detected from day 40 in the saline
and glucose model; however, no toxin production was detected in
the trehalose model, despite 42 daily measurements (days 14–55).
Post-clindamycin changes in themicrobial populations showed quicker
recoveries in the glucose/trehalose models of key bacterial populations,
such as Biﬁdobacterium spp. (peak recovery at day 36 and 38, respec-
tively) and Bacteroides spp. (day 38 and 35), compared with recoveries
from saline (day 41 and 39) supplemented model (Fig. S3).
4. Discussion
Convincing evidence, including molecular experiments using gene
deletions and recombinants, demonstrates that trehalose metabolism
variants in C. difﬁcile confer the ability tometabolise low concentrations
of trehalose and that this provides a competitive advantage in growth
media and laboratory animals [6]. However, we have shown here that
trehalose metabolism variants are widespread in multiple distinct
C. difﬁcile genotypes causing human infections, representing genetically
divergent C. difﬁcile clades. The treRmutations conferring the L172I and
C171S substitutions are ancient and widely conserved within clades
2 and 4 respectively. Similarly, the genetic diversity within the four-
gene cluster follows the C. difﬁcile population structure. While the
importance of trehalose metabolism variants in the success of
ribotype-027 and ribotype-078 cannot be discounted, other hypotheses
are required to explain why these lineages have been so successful
when many other lineages with the same trehalose metabolism vari-
ants, many from the same clades, have not been.
In contrast, acquisition of antimicrobial resistance does distinguish
many of the successful lineages, in particularﬂuoroquinolone resistance
in ribotype 027, 001, 176, 018/356, which have all been associated with
healthcare, and local and national clustering of C. difﬁcile [3]. Although
ribotype-078 lacks consistent ﬂuoroquinolone resistance, this may be
less relevant to its success, which has been supported by a strong agri-
cultural niche. Ribotype-078 is widely tetracycline resistant and animal
tetracycline administration may be important in promoting its
spread [30]. Notably, unlike the healthcare-associated ribotypes above,
it does not exhibit phylogeographic structure, but instead is widely-
distributed suggesting dissemination via the food chain or another sim-
ilar route [3].Please cite this article as: D.W. Eyre, X. Didelot, A.M. Buckley, et al., Clostrid
ciated with adverse patient outcomes when variably present..., EBioMedicWithin ribotype-027, the TreR L172I variant is associated with in-
creased mortality in the presence of dietary trehalose in a mouse
model of CDI [6]. Both ribotype-027 (ST1) and ribotype-078 (ST11)
have been associated with increased patient mortality [31] and contain
different trehalose metabolism variants. However, these lineages differ
by 10,000 s to 100,000 s of SNPs from other control lineages used in out-
come studies. Therefore, distinguishing which mutation, gene, or genes
are responsible for this phenotype is challenging. An attempt to associ-
ate one mutation, e.g. that leading to the TreR L172I substitution, with
outcome will be potentially confounded by the many other SNPs that
deﬁne each clade. Within C. difﬁcile ribotype-015, the trehalose four-
gene cluster is variably present and absent, providing an opportunity
to test for an association with mortality in patients with considerably
fewer potentially confounding SNPs. In a population of patients likely
to be widely representative of those with CDI, i.e. from consecutive un-
selected cases in twoUK centres and from the two ﬁdaxomicin licensing
trials in the USA, Canada and Europe, we found no evidence that the
four-gene cluster was associated with increased 30-day all-cause mor-
tality following CDI with ribotype-015. We did not ﬁnd other examples
of common ribotypes with and without trehalose metabolism variants
and so were unable to test this ﬁnding in other lineages. It is therefore
possible that differences in strain background or species differences in
intestinal microbiomes could explain the discrepancies between these
human ﬁndings and previous experimental mouse models.
Given trehalosemetabolism variants have likely been stably present
within C. difﬁcile for thousands of years, recent changes in dietary treha-
lose have been hypothesised to have enabled trehalose metabolism to
play signiﬁcant role in the emergence of ribotypes 027 and 078 [6].
Low cost productionmethods for synthesis of trehalosewere developed
in the 1990s by Hayashibara Co. Ltd., with approval for use in food
granted ﬁrst in Japan in 1995, and then in the USA in 2000, Europe in
2001 and Canada in 2005. Collins et al estimated that 21 g of trehalose
is consumed per person annually from naturally occurring trehalose in
mushrooms andhoney, two trehalose rich foods, based on consumption
ﬁgures from the USA. This was extrapolated to estimate that the total
naturally occurring dietary trehalose intake may be ~100 g per capita
per year [7]. The Food and Drug Administration GRAS (generally
recognised as safe) submission from Hayashibara International Inc. in
2000, notes potential for consumption of up to 34 g of trehalose a day
based on levels of trehalose use in foods in Japan and consumption
levels of these foods in the USA. However, as shown in Fig. 3A, imports
of trehalose between 2000 and 2012 in the USA and Europewere only a
fraction of these levels, b1 g per capita per year from 2000 to 2006, and
b 9 g per capita per year until 2012. Therefore, synthetic trehalose im-
ports did not signiﬁcantly alter the total dietary intake of trehalose, par-
ticularly during the 2000–2006 when overall incidence of CDI rose
substantially in the USA and England, driven by the spread of
ribotype-027 [4] (Fig. 3B).
A potential weakness of using import data is that trehalose may be
used in food production and then exported and consumed in other
countries. Therefore, we explored the example of England in more de-
tail. England contains the 84% of the UK population. The large majority
of food consumed in the UK is sourced from the UK and EU, with only
4% from North America [32]. If we make the unlikely, but conservative
assumption that all trehalose imported into the EU was consumed in
the UK, rather than elsewhere or used for manufacturing development,
then b1 g of trehalose per capita per year was consumed in between
2000 and 2005 inclusive, i.e. b1% of naturally occurring consumption
[7]. During this time large outbreaks of ribotype-027 occurred [33]. Sim-
ilarly, up until 2012 the per capita imports to theUS only reached a peak
of 3.7 g per year in 2007, and were b 1 g per year until 2006, while rises
in ribotype-027 cases [34] and total CDI incidence [18] were reported
from 2000 onwards. In Canada, trehalose was only licenced for use in
2005; however, a large outbreak of ribotype-027 was reported in Que-
bec Province from 2003 onwards [35]. Although changes in CDI inci-
dence have been largely driven by changes in ribotype-027, aium difﬁcile trehalose metabolism variants are common and not asso-
ine, https://doi.org/10.1016/j.ebiom.2019.04.038
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analyse temporal trends in lineages with and without trehalose metab-
olism variants as these are not captured by the national surveillance
data used. Another limitation of our approach is that we assume syn-
thetic trehalose is consumed uniformly by a population, however
supporting this, we are not aware of any evidence to suggest synthetic
trehalose is consumed preferentially by those most at risk of CDI.
In a chemostat gut model of CDI representative of human CDI, sup-
plementation of trehalose did not result in increased levels of
C. difﬁcile or its spores compared with glucose or saline supplementa-
tion. Additionally, supplementation with trehalose actually reduced
toxin detection to undetectable levels. To incorporate themany gut mi-
crobial families identiﬁed in humans, we used a pooled slurry from 5
healthy donors in our gutmodel. However, we acknowledge the limita-
tion that our model experiment was only run once for each set of test
conditions, which limits the generalisability of these data. However,
the multiple longitudinal measurements over 8 weeks, from this well
studied model, represent replicates of the measurements obtained.
The data from these preliminary models highlight several potential
areas for further study. Trehalose is readily metabolised into two glu-
cose molecules by the human intestinal ﬂora through production of
trehalase. High glucose levels have been shown to repress C. difﬁcile
tcdA and tcdB expression, via the regulator CcpA [36], which could ex-
plain the low levels of toxin detected during glucose supplementation,
subsequent increases after dosing stopped, and also the absence of
toxin production during/after trehalose administration. The difference
in the effect of trehalose in our model compared with previously pub-
lished ﬁndings [6] could be attributed to, either the difference in the in-
testinal ﬂora between humans and mice, or as part of an immune
system response, not accounted for in our system. Here, we did not
measure expression of treA from the models, as any results obtained
could not be assigned to our C. difﬁcile strain given that many other
human intestinal bacterial species also express treA. Our dosing sched-
ule allowed us to set the concentration of trehalose and glucose in the
ﬁrst vessel of the model, however we do not have data available on
the levels achieved in the second and third vessels.
Themain part of our study is based on genomic analysis and does not
include functional assessment of the relative ﬁtness of the strains stud-
ied. However, it provides a basis for such work to be carried out in the
future. Additionally, the power of our study to detect a mortality differ-
ence in the ribotype-015 infections with and without the four-gene
cluster is limited by the relatively lowoverall rate ofmortality in this pa-
tient group, 15%, and the sample size. However, the 30-day all-cause
mortality for ribotype-027 and ribotype-078 is approximately 30%
[31]; a study of a similar size to ours (n= 200, with equal proportions
with and without the four-gene cluster) would have 95% power to de-
tect a difference in outcome of for example 10% versus 30%.
In conclusion, we ﬁnd that trehalose metabolism variants are com-
monwithin the overall genetic diversity of C. difﬁcile. Consequently, ad-
ditional explanations are required to explain why ribotype-027 and
ribotype-078 have been successful when many other lineages sharing
the same variants have not. Increases in total dietary trehalose were
minimal as a proportion of total dietary trehalose intake, and therefore
very unlikely to have contributed signiﬁcantly to the emergence and
spread of ribotype-027 and ribotype-078.Funding sources
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